ASCO Announces CancerLinQ Discovery® Research Support Grant Recipients

August 15, 2019

ASCO has announced the three recipients of its CancerLinQ Discovery® Research Support Grant. The awardees will undertake research projects using data from CancerLinQ Discovery®, an offering of ASCO’s CancerLinQ® initiative that provides de-identified data from cancer patients to academic researchers, government agencies, and others in the oncology community to generate practical knowledge that will improve cancer care.

“We are proud to support a new group of researchers using the real-world evidence in CancerLinQ Discovery®,” said ASCO Chief Medical Officer Richard L. Schilsky, MD, FACP, FSCT, FASCO. "The findings from these three research projects have the potential to inform and improve the treatment of breast, lung, and prostate cancer.”

CancerLinQ® collects and analyzes real-world data from patients at practices nationwide, drawing from electronic health records. The CancerLinQ Discovery® de-identified data sets are derived from the vast pool of data contributed by participating practices. The research projects funded by this grant are consistent with ASCO’s mission to conquer cancer through research, education, and promotion of the highest quality patient care; are being addressed using CancerLinQ Discovery® data; and will publish the findings in medical journals.

The recipients of the CancerLinQ Discovery® Research Support Grant and their projects are as follows:

  • Yasmin Karimi, MD, with Stanford University School of Medicine will examine the real-world utilization and efficacy of osteoclast inhibitors on skeletal related events and mortality in patients with metastatic breast cancer and known bone metastasis.
  • Vinayak Muralidhar, MD, MSc, with Brigham and Women’s Hospital and the Harvard Radiation Oncology Program will explore contemporary patterns of care regarding the use of androgen deprivation therapy and hypofractionation in prostate cancer.
  • Sadiq Rehmani, MD, with Icahn School of Medicine at Mount Sinai will study outcomes with immunotherapy in the management of lung cancer patients with advanced age and comorbidities.

The grants are being funded by the Mission Endowment of Conquer Cancer®, The ASCO Foundation. Each one-year grant covers the cost of a CancerLinQ Discovery® data set and a kickoff meeting at ASCO headquarters and contributes to personnel and/or research expenses.

Conquer Cancer Mission Endowment provides a long-term base of support to advance the foundation’s critical mission to improve the care and treatment of people living with cancer. The endowment is the cornerstone of its efforts to extend the reach and impact of its work and allows Conquer Cancer to continue to support the very best opportunities for scientific research, professional development, and patient education well into the future. Mission Endowment provides a stable flow of funds to increase grant funding, sustain existing programs, develop new initiatives, and reach new audiences around the world.

CancerLinQ® and CancerLinQ Discovery® are projects of CancerLinQ LLC. For more information about either initiative, please go to